Thrombopenia Clinical Trial
The purpose of this study is to review the charts of the first 100 patients included in the french compassionate program including patients with Immune Thrombopenia receiving romiplostim.
Inclusion Criteria:
- Subject has a diagnosis of ITP according to the American Society of Hematology
guidelines (George et al., 1996).
- Subject is equal to or greater than 18 years of age.
- Before any study-specific procedure, the appropriate written informed consent must be
obtained.
- Subject receiving romiplostim in the compassionate program
- Available follow-up of one-year
Exclusion Criteria:
•Secondary ITP e.g: thrombopenia related to hepatitis C, HIV, Chronic Lymphocytic
Leukemia...
The goal of this study is to review retrospectively the charts of the 100 first patients
including in this program in France during the period of January 2008 and July 2008.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05040776 -
COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients
|
Phase 2 | |
| Recruiting |
NCT02906878 -
Platelet Kinetics After Platelet Transfusion for the Placement of a Central Venous Catheter
|
N/A | |
| Completed |
NCT00336687 -
Study of Incidence, of Mechanisms and Prognosis of the Thrombopenia From Patients of Reanimation.
|
N/A | |
| Not yet recruiting |
NCT03823079 -
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
|
Phase 2 | |
| Completed |
NCT04070599 -
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.
|
Phase 3 |